Clinical Trial Update: Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating dexamethasone plus ixazomib versus physician's choice in relapsed or refractory systemic light chain (AL) amyloidosis was terminated,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Light Chain Amyloidosis

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• ixazomib (ixazomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Relapsed or Refractory Systemic Light Chain Amyloidosis | Phase 3 | Status: TERMINATED | Results posted: 2023-09-21